Novo Nordisk aims to launch more than five blockbuster drugs by 2030, CEO says
21/09/2026 10:04
Novo Nordisk aims to launch more than five blockbuster drugs by 2030, CEO says LONDON, Sept 21 (Reuters) - Novo Nordisk NOVOb.CO aims to launch more than five blockbuster drugs by 2030 and to deliver more than 150 billion Danish crowns ($23 billion) in pipeline sales in 2035, its CEO Mike Doustdar said at a Capital Markets Day in London.
($1 = 6.5096 Danish crowns)
(Reporting by Patrick Wingrove, writing by Louise Rasmussen; Editing by Emelia Sithole-Matarise)
((Louisebreusch.rasmussen@tr.com; +45 21 27 97 79;))
Recent news on Novo Nordisk A/S
See all newsFocus: Beauty giants target 'Ozempic face' as boom in obesity drugs opens new market
Factbox: Anthropic's public benefit fund and how it compares with other big philanthropic efforts
Novo's CagriSema helped women lose 25% of weight on average, analysis shows
As weight-loss drug users turn to dietary supplements, doctors, regulators raise flags
Factbox: Major drugmakers turn to China for licensing deals